<div id="readability-page-1"><div><p>(MT Newswires) -- Centene (CNC) expects all of its business segments to improve in 2026 as the company continues to focus on driving margin across its portfolio after reaffirming its 2025 adjusted earnings per share guidance and providing &#34;positive commentary&#34; in key business lines, Truist Securities said in a Friday note.</p><p> In a recent conference presentation, Centene highlighted the incremental progress in its health benefits ratio for Medicaid, in line with its target of H2 segment ratio improvement. For its Marketplace segment, Centene has refiled rates in states covering about 95% of its membership, a majority of which have already been approved, Truist said.</p><p> For Medicare, preliminary data indicate Stars trends to be in-line with management's expectations, with a possibility for 4-Star plans membership percentage to be &#34;a bit better than expected,&#34; the investment firm added.</p><p> &#34;While the environment continues to carry areas of uncertainty we are encouraged by the company's update,&#34; Truist said.</p><p> Truist raised its price target on Centene to $39 from $35 and reiterated its buy rating.</p><p>Price: 33.99, Change: -0.09, Percent Change: -0.26</p></div></div>

康西哥

<p>Centene (CNC) 预计到 2026 年所有业务部门将实现改善，重点关注利润提升。根据 Truist Securities 的报告，该公司重申了 2025 年调整后每股收益的指引，并收到了对关键业务线的积极反馈。医疗补助的健康福利比率的进展符合目标，大多数重新提交的市场费率已获得批准。医疗保险的星级趋势符合预期，4 星计划有潜力超出预期。Truist 将 Centene 的目标股价从 35 美元上调至 39 美元，维持买入评级。当前股价：33.99 美元，下跌 0.26%</p>

Truist 证券表示，康西哥预计其业务板块将在 2026 年有所改善